Incyte have announced that the FDA (U.S. Food and Drug Administration) have granted marketing approval for 
Jakafi™ (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythaemia vera MF and post-essential thrombocythaemia MF. Patients with intermediate and high-risk MF represent 80 to 90 percent of MF patients. Jakafi (JAK-ah-fye) is the first and only product to be approved by the FDA for MF, and the first in a new class of drugs, known as JAK inhibitors, to be approved for any indication. Jakafi is an oral JAK1 and JAK2 inhibitor.
You can read the full press release here.
Incyte is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary, orally available drugs for serious unmet medical needs in oncology and inflammation. For more information visit the Incyte website.